Deerfield Management SDGR Position
ExitedDeerfield Management exited their position in Schrodinger Inc. (SDGR) in Q3 2024, after holding the stock for 2 quarters.
The position was first reported in Q2 2024 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds SDGR.
Short interest stands at 27.9% of float with 7.9 days to cover, indicating significant bearish positioning against the stock.
About Schrodinger Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Full company profile →Short Interest
27.9%
7.9 days to cover
Deerfield Management SDGR Position History
Frequently Asked Questions
Does Deerfield Management own SDGR?
No. Deerfield Management exited their position in Schrodinger Inc. (SDGR) in Q3 2024. They previously held the stock for 2 quarters.
How many hedge funds own SDGR?
1 specialist biotech hedge fund currently holds SDGR, including Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy SDGR?
Deerfield Management's position in SDGR was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's SDGR position increasing or decreasing?
Deerfield Management completely exited their SDGR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SDGRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →